US20110257140A1 - Biomarkers of Mineralocorticoid Receptor Activation - Google Patents

Biomarkers of Mineralocorticoid Receptor Activation Download PDF

Info

Publication number
US20110257140A1
US20110257140A1 US13/124,575 US200913124575A US2011257140A1 US 20110257140 A1 US20110257140 A1 US 20110257140A1 US 200913124575 A US200913124575 A US 200913124575A US 2011257140 A1 US2011257140 A1 US 2011257140A1
Authority
US
United States
Prior art keywords
patient
ngal
sample
serpina3
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/124,575
Other languages
English (en)
Inventor
Frederic Jaisser
Nicolette Farman
Yannis Sainte-Marie
Celine Latouche
Marja Steenman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite de Nantes
Institut National de la Sante et de la Recherche Medicale INSERM
Universite Paris 5 Rene Descartes
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Priority to US13/124,575 priority Critical patent/US20110257140A1/en
Assigned to INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) reassignment INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LATOUCHE, CELINE, SAINTE-MARIE, YANNIS, STEENMAN, MARJA, FARMAN, NICOLETTE, JAISSER, FREDERIC
Publication of US20110257140A1 publication Critical patent/US20110257140A1/en
Assigned to UNIVERSITÉ PARIS DESCARTES, Université de Nantes reassignment UNIVERSITÉ PARIS DESCARTES ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: Institut National de la Santé et de la Recherche Médicale
Assigned to INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, UNIVERSITE DE NANTES, UNIVERSITE PARIS DESCARTES reassignment INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE CORRECTIVE ASSIGNMENT TO CORRECT THE OWNER OF THE PATENT RIGHTS. ASSIGNMENT IS NOT FOR ENTIRE INTEREST, BUT AN ASSIGNMENT IN PART. PREVIOUSLY RECORDED ON REEL 033858 FRAME 0145. ASSIGNOR(S) HEREBY CONFIRMS THE CONVEYING PARTY ASSIGNS ENTIRE INTEREST. Assignors: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/321—Arterial hypertension
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Definitions

  • the present invention relates to biomarkers of the Mineralocorticoid Receptor (MR) activation in a patient.
  • MR Mineralocorticoid Receptor
  • Mineralocorticoid receptor is a member of the classic steroid hormone receptors that include glucocorticoid receptor (GR), androgen receptor (AR), progesterone receptor (PR), and estrogen receptor (ER) (Funder, 1997). These receptors are hormone-activated transcriptional factors that regulate a wide variety of physiological processes ranging from organ development and differentiation to mood control and stress response (Beato et al., 1995).
  • the physiological hormone for MR is aldosterone which is a steroid hormone secreted by the adrenal gland.
  • MRs have been located on non-epithelial sites in blood vessels, brain, and heart (Bonvalet J P. et al. 1995; Lombes M, et al. 1992; Tanaka J. et al. 1997). Numerous studies over the past 10 years suggest that the non-epithelial actions of mineralocorticoids are responsible for their vascular and myocardial fibrotic and trophic effects (Brilla C G. et al. 1992, Ullian M E. et al. 1992; Young M. et al. 1994) In addition, MRs have been discovered, including human endothelial cells and vascular smooth muscle cells (VSMC) (Hatakeyama H. et al.
  • VSMC vascular smooth muscle cells
  • MR Farquharson C A. et al. (2000) indirectly showed that aldosterone could have a role in endothelial dysfunction in chronic heart failure. Therefore MR is an important drug target particularly for the treatment of hypertension and heart failure.
  • the aldosterone antagonist spironolactone (also known as ALDACTONE®, PFIZER) binds to the mineralocorticoid receptor and blocks the binding of aldosterone.
  • ALDACTONE® PFIZER
  • This steroidal compound is used commonly in the treatment of congestive heart failure.
  • spironolactone has been shown to be pharmacologically effective and well tolerated, to reduce the overall risks of death, death due to progressive heart failure, and sudden death from cardiac causes, as well as the risk of hospitalization for cardiac causes.
  • the administration of spironolactone to severe heart failure patients was evaluated in the Randomized Aldactone Evaluation Study (RALES).
  • RALES was a randomized, double-blinded, placebo-controlled trial that enrolled participants who had severe heart failure and a left ventricular ejection fraction of no more than 35% and who were receiving standard therapy, which typically included an angiotensin-converting enzyme inhibitor, a loop diuretic, and, in some cases, digoxin.
  • standard therapy typically included an angiotensin-converting enzyme inhibitor, a loop diuretic, and, in some cases, digoxin.
  • the RALES subjects treated with spironolactone had a statistically significant reduction in mortality and incidence of hospitalization relative to placebo-treated subjects (Pitt B. et al. 1999).
  • eplerenone exemplifies another blocker of aldosterone binding at the mineralocorticoid receptor. Its action is selective, in that eplerenone binds to recombinant human mineralocorticoid receptors in preference to binding to recombinant human glucocorticoid, progesterone and androgen receptors. The therapeutic benefits associated with administration of eplerenone have been demonstrated in multiple clinical trials.
  • aldosterone is not the only endogenous hormone known for activating the MR.
  • endogenous glucocorticoids can also activate the MR.
  • glucocorticoids have been shown to produce oxidative stress and vascular inflammation at the earliest stages of the development of cardiac fibrosis. Deleterious effects of MR activation in the cardiovascular system may thus occur even in the absence of hyperaldosteronism (Funder J W, 2006) and plasma levels of aldosterone do not provide indication on the MR activation in the cardiovascular system.
  • MR expression is increased in heart or vessels in heart failure, cardiac infarction or end-organ damage associated to high blood pressure (Nagata K, et al. 2006; Takeda M. et al., 2007).
  • MR antagonist in a patient may be accompanied with serious adverse side effects such as hyperkalemia.
  • hyperkalemia there have been several reports of serious hyperkalemia following the publication of the RALES study. In one such report, no less than 25 patient episodes of spironolactone-related hyperkalemia that had to be treated in the emergency room were described (Schepkens H. et al. 2001). Four of the 25 patients required cardiovascular resuscitation measures, and 2 of the 25 patients died. Several authors have estimated an incidence of clinically significant hyperkalemia of about 10% in patients receiving this MR antagonist.
  • the present invention relates to a method for assessing the Mineralocorticoid Receptor (MR) activation in a patient comprising determining in a biological sample obtained from said patient the expression level of one or two biomarkers selected from the group consisting of the Neutrophil Gelatinase-Associated Lipocalin (NGAL) gene and the SERPINA3 gene.
  • MR Mineralocorticoid Receptor
  • the present invention also relates to a method for predicting the responsiveness of a patient to a treatment with a MR antagonist or an aldosterone synthase inhibitor, said method comprising determining in a biological sample obtained from said patient the expression level of one or two biomarkers selected from the group consisting of the Neutrophil Gelatinase-Associated Lipocalin (NGAL) gene and the SERPINA3 gene.
  • NGAL Neutrophil Gelatinase-Associated Lipocalin
  • the invention also relates to the use of a MR antagonist or an aldosterone synthase inhibitor, for treating a patient affected with a cardiovascular disease, diabetes, obesity or metabolic syndrome, said patient being classified as responder by the method of the invention.
  • MR refers to the mineralocorticoid receptor.
  • MR activation refers to the activation of the mineralocorticoid receptor by mineralocorticoids (i.e. aldosterone) or glucocorticoids.
  • MR antagonist refers to a compound, natural or not, which has the capability to inhibit (partly or totally) the biological activation of the MR.
  • a number of MR antagonists are known including spironolactone, epoxymexrenone and eplerenone.
  • the scope of the present invention includes all those MR antagonists now known and those MR antagonists to be discovered in the future.
  • the aldosterone antagonist may be a spironolactone-type compound (Spironolactone, active metabolites of spironolactone such as canrenone or salts thereof such as potassium canrenoate).
  • the aldosterone antagonist may also be an epoxy-steroidal aldosterone antagonist.
  • MR antagonists Another series of steroidal-type MR antagonists is exemplified by epoxy-containing spironolactone derivatives.
  • U.S. Pat. No. 4,559,332 describes spironolactone derivatives as MR antagonists.
  • a further MR antagonist may be Drospirenone (DRSP), which is an analogue to Spironolactone.
  • DRSP Drospirenone
  • aldosterone synthase inhibitor is intended to include compounds or agents that inhibit the aldosterone synthase enzyme, which convert corticosterone to aldosterone by hydroxylating corticosterone to form 18-OH-corticosterone and 18-OH-corticosterone to aldosterone.
  • aldosterone synthase inhibitors are well known in the art. The scope of the present invention includes all those aldosterone synthase inhibitors now known and those aldosterone synthase inhibitors to be discovered in the future. Said aldosterone synthase inhibitor may be steroidal or non-steroidal aldosterone synthase inhibitors.
  • the aldosterone synthase inhibitor may be a non-steroidal or steroidal aromatase inhibitor.
  • Non-steroidal aromatase inhibitors may include anastrozole and fadrozole (including the (+)-enantiomer thereof).
  • An example of a steroidal aromatase inhibitor is exemestane.
  • Another non-steroidal aldosterone synthase inhibitor is the (+)-enantiomer of the hydrochloride of fadrozole (U.S. Pat. Nos. 4,617,307 and 4,889,861) as also described in Fiebeler A. et al. (2005).
  • NGAL has its general meaning in the art and refers to the Neutrophil Gelatinase-Associated Lipocalin as described in Schmidt-Ott K M. et al. (2007).
  • NGAL can be from any source, but typically is a mammalian (e.g., human and non-human primate) NGAL, particularly a human NGAL.
  • NGAL gene refers to any nucleotide sequence encoding the NGAL mRNA and protein, such as a genomic DNA sequence and any naturally occurring NGAL and variants and modified forms thereof. It can also encompass artificial sequences such as cDNA encoding the NGAL mRNA and protein.
  • GenBank database under accession number NM — 005564.
  • NGAL mRNA has its general meaning in the art and refers to the messenger RNA which is synthesized upon expression of the NGAL gene.
  • NGAL protein refers to the amino acid sequence resulting from the expression of the NGAL gene, and any naturally occurring NGAL and variants and modified forms thereof.
  • GenPept database under accession number NP — 005555.
  • NGAL protein as used herein also encompasses the heterodimeric complex formed by NGAL and the metalloproteinase MMP-9, also known as gelatinase B, 92 kDa type IV collagenase, 92 kDa gelatinase and type V collagenase (Kjeldsen et al., 1993).
  • anti-NGAL antibody refers to an antibody or a fragment thereof which recognizes NGAL.
  • SERPINA3 has its general meaning in the art, it is also known as CT; AACT; GIG24; GIG25; MGC88254. The official full name of this gene is serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3.
  • SERPINA3 can be from any source, but typically is a mammalian (e.g., human and non-human primate) SERPINA3, particularly a human SERPINA3.
  • SERPINA3 gene refers to any nucleotide sequence encoding the SERPINA3 mRNA and protein, such as a genomic DNA sequence and any naturally occurring SERPINA3 and variants and modified forms thereof.
  • SERPINA3 mRNA has its general meaning in the art and refers to the messenger RNA which is synthesized upon expression of the SERPINA3 gene.
  • SERPINA3 protein refers to the amino acid sequence resulting from the expression of the SERPINA3 gene, and any naturally occurring SERPINA3 and variants and modified forms thereof.
  • SERPINA3 antibody refers to an antibody or a fragment thereof which recognizes the SERPINA3 protein.
  • cardiovascular system has its general meaning in the art, and denotes the system composed of the heart, blood vessels, or vasculature, and the cells and plasma that make up the blood.
  • Cardiovascular disease has its general meaning in the art and is used to classify numerous conditions that affect the heart, heart valves, blood, and vasculature of the body. Cardiovascular diseases include endothelial dysfunction, coronary artery disease, angina pectoris, myocardial infarction, congestive heart failure, hypertension, cerebrovascular disease, stroke, transient ischemic attacks, deep vein thrombosis, peripheral artery disease, cardiomyopathy, arrhythmias, aortic stenosis, and aneurysm.
  • the term “predetermined value of a biomarker” refers to the amount of the biomarker in biological samples obtained from the general population or from a selected population of subjects.
  • the selected population may be comprised of apparently healthy subjects, such as individuals who have not previously had any sign or symptoms indicating the presence of cardiovascular disease.
  • the predetermined value may be of the amount of biomarker obtained from subjects having an established cardiovascular disease.
  • the predetermined value can be a threshold value, or a range.
  • the predetermined value can be established based upon comparative measurements between apparently healthy subjects and subjects with established cardiovascular disease.
  • a patient denotes a mammal such as a rodent, a feline, a canine and a primate.
  • a patient according to the invention is a human.
  • a “responder” or “responsive” patient, or group of patients, to a treatment with a MR antagonist or with an aldosterone synthase inhibitor refers to a patient, or group of patients, who shows or will show a clinically significant relief in the cardiovascular disease when treated with a MR antagonist or with an aldosterone synthase inhibitor, respectively.
  • a patient is classified as a responder to a treatment if the expression of one or two biomarkers selected from the group consisting of the Neutrophil Gelatinase-Associated Lipocalin (NGAL) gene and the SERPINA3 gene, in said patient is significantly different from the predetermined value obtained from the general population or from healthy subjects.
  • NGAL Neutrophil Gelatinase-Associated Lipocalin
  • a patient is a responder if the expression level of one or two biomarkers selected from the group consisting of the Neutrophil Gelatinase-Associated Lipocalin (NGAL) gene and the SERPINA3 gene, in said patient is higher than the predetermined value obtained from the general population or from healthy subjects.
  • NGAL Neutrophil Gelatinase-Associated Lipocalin
  • the expression level of said one or two biomarkers in a patient is deemed to be higher than the predetermined value obtained from the general population or from healthy subjects if the ratio of the expression level of said one or two biomarkers in said patient to that of said predetermined value is higher than 1.2, preferably 1.5, even more preferably 2, even more preferably 5, 10 or 20.
  • health subjects refers to a population of subjects who do not suffer from any known condition, and in particular, who are not affected with any cardiovascular disease, diabetes, obesity, or metabolic syndrome.
  • biological sample means any biological sample derived from a patient. Examples of such samples include fluids, tissues, cell samples, organs, biopsies, etc. Preferred biological samples are a cell or tissue sample. Preferred biological samples are whole blood, serum, plasma or urine.
  • biomarker refers generally to a molecule, i.e., a gene (or nucleic acid encoding said gene), protein, the expression of which in a biological sample from a patient can be detected by standard methods in the art (as well as those disclosed herein), and is predictive or denotes a condition of the patient from which it was obtained.
  • the present invention relates to a method for assessing the MR activation in a patient comprising determining in a biological sample obtained from said patient the expression level of one or two biomarkers selected from the group consisting of the Neutrophil Gelatinase-Associated Lipocalin (NGAL) gene and the SERPINA3 gene.
  • NGAL Neutrophil Gelatinase-Associated Lipocalin
  • the invention relates to a method for assessing the MR activation in the cardiovascular system of said patient comprising determining in a biological sample obtained from said patient the expression level of one or two biomarkers selected from the group consisting of the Neutrophil Gelatinase-Associated Lipocalin (NGAL) gene and the SERPINA3 gene.
  • NGAL Neutrophil Gelatinase-Associated Lipocalin
  • the present invention also relates to a method for predicting the responsiveness of a patient to a treatment with a MR antagonist or an aldosterone synthase inhibitor, said method comprising determining in a biological sample obtained from said patient the expression level of one or two biomarkers selected from the group consisting of the Neutrophil Gelatinase-Associated Lipocalin (NGAL) gene and the SERPINA3 gene.
  • NGAL Neutrophil Gelatinase-Associated Lipocalin
  • the patient is affected with a cardiovascular disease. More particularly, said patient is affected with endothelial dysfunction, coronary artery disease, angina pectoris, myocardial infarction, congestive heart failure, hypertension, cerebrovascular disease, stroke, transient ischemic attacks, deep vein thrombosis, peripheral artery disease, cardiomyopathy, arrhythmias, aortic stenosis, or aneurysm. In a particular embodiment, said patient is affected with congestive heart failure or hypertension.
  • the patient with a cardiovascular disease has already been treated with a standard treatment selected in the group consisting of angiotensin-converting enzyme inhibitor, diuretics, vasodilators, beta-blockers, digitalis, and anticoagulants.
  • a standard treatment selected in the group consisting of angiotensin-converting enzyme inhibitor, diuretics, vasodilators, beta-blockers, digitalis, and anticoagulants.
  • the patient is affected with obesity, diabetes or metabolic syndrome.
  • MR activation was associated with the pathophysiological development of obesity and metabolic syndrome (Caprio M. et al. 2007; Lamounier-Zepter V. et al. 2005).
  • the invention relates to a method for assessing the MR activation in a patient comprising determining the quantity of the one or two biomarkers mRNA in a cell or tissue sample obtained from said patient.
  • the present invention also relates to a method for predicting the responsiveness of a patient to a treatment with a MR antagonist or an aldosterone synthase inhibitor, said method comprising determining the quantity of the one or two biomarkers mRNA in a cell or tissue sample obtained from said patient.
  • PBMCs Peripheral blood mononuclear cells
  • EPCs endothelial cells and endothelial promoter cells
  • PBMCs Peripheral blood mononuclear cells
  • EPCs endothelial cells and endothelial promoter cells
  • RNAs can be easily extracted therefrom.
  • the cell or tissue sample may be treated prior to its use, e.g. in order to render nucleic acids available. Techniques of cell or protein lysis, concentration or dilution of nucleic acids, are known by the skilled person.
  • Determination of the expression level of a gene can be performed by a variety of techniques. Generally, the expression level as determined is a relative expression level.
  • the determination comprises contacting the sample with selective reagents such as probes, primers or ligands, and thereby detecting the presence, or measuring the amount of nucleic acids of interest originally in the sample.
  • selective reagents such as probes, primers or ligands
  • the expression level may be determined by determining the quantity of mRNA.
  • the nucleic acid contained in the samples e.g., cell or tissue prepared from the patient
  • the extracted mRNA is then detected by hybridization (e.g., Northern blot analysis) and/or amplification (e.g., RT-PCR).
  • hybridization e.g., Northern blot analysis
  • amplification e.g., RT-PCR
  • the expression level of the one or two biomarkers is determined by RT-PCR, preferably quantitative or semi-quantitative RT-PCR, even more preferably real-time quantitative or semi-quantitative RT-PCR.
  • the expression level of the NGAL gene is assessed by quantitative PCR using forward 5′-GGACCAGGGCTGTCGCTACT-3′ (SEQ ID NO:1) and Reverse 5′-GGTGGCCACTTGCACATTGT-3′ (SEQ ID NO:2) primers, or forward 5′-TCACCCTGTACGGAAGAACC-3′ (SEQ ID NO:3) and reverse 5′-GGTGGGAACAGAGAAAACGA-3′ (SEQ ID NO:4) primers.
  • LCR ligase chain reaction
  • TMA transcription-mediated amplification
  • SDA strand displacement amplification
  • NASBA nucleic acid sequence based amplification
  • Nucleic acids having at least 10 nucleotides and exhibiting sequence complementarity or homology to the mRNA of interest herein find utility as hybridization probes or amplification primers. It is understood that such nucleic acids need not be identical, but are typically at least about 80% identical to the homologous region of comparable size, more preferably 85% identical and even more preferably 90-95% identical. In certain embodiments, it will be advantageous to use nucleic acids in combination with appropriate means, such as a detectable label, for detecting hybridization. A wide variety of appropriate indicators are known in the art including, fluorescent, radioactive, enzymatic or other ligands (e.g. avidin/biotin).
  • Probes typically comprise single-stranded nucleic acids of between 10 to 1000 nucleotides in length, for instance of between 10 and 800, more preferably of between 15 and 700, typically of between 20 and 500.
  • Primers typically are shorter single-stranded nucleic acids, of between 10 to 25 nucleotides in length, designed to perfectly or almost perfectly match a nucleic acid of interest, to be amplified.
  • the probes and primers are “specific” to the nucleic acids they hybridize to, i.e. they preferably hybridize under high stringency hybridization conditions (corresponding to the highest melting temperature Tm, e.g., 50% formamide, 5 ⁇ or 6 ⁇ SCC. SCC is a 0.15 M NaCl, 0.015 M Na-citrate).
  • the nucleic acid primers or probes used in the above amplification and detection method may be assembled as a kit.
  • a kit includes consensus primers and molecular probes.
  • a preferred kit also includes the components necessary to determine if amplification has occurred.
  • the kit may also include, for example, PCR buffers and enzymes; positive control sequences, reaction control primers; and instructions for amplifying and detecting the specific sequences.
  • the invention in another embodiment, relates to a method for assessing the MR activation of a patient comprising measuring the concentration of the one or two biomarkers proteins in a biological sample obtained from said patient.
  • the invention in another embodiment, relates to a method for predicting the responsiveness of a patient to a treatment with a MR antagonist or an aldosterone synthase inhibitor comprising measuring the concentration of the one or two biomarkers proteins in a biological sample obtained from said patient.
  • the concentration of the one or two biomarkers protein is measured in a blood sample, a plasma sample, a serum sample or a urine sample obtained from said patient.
  • the methods of the invention comprise contacting the biological sample with a binding partner capable of selectively interacting with the one or two biomarkers proteins present in the biological sample.
  • the binding partner may be an antibody that may be polyclonal or monoclonal, preferably monoclonal. In another embodiment, the binding partner may be an aptamer.
  • Polyclonal antibodies of the invention or a fragment thereof can be raised according to known methods by administering the appropriate antigen or epitope to a host animal selected, e.g., from pigs, cows, horses, rabbits, goats, sheep, and mice, among others.
  • a host animal selected, e.g., from pigs, cows, horses, rabbits, goats, sheep, and mice, among others.
  • Various adjuvants known in the art can be used to enhance antibody production.
  • antibodies useful in practicing the invention can be polyclonal, monoclonal antibodies are preferred.
  • Monoclonal antibodies of the invention or a fragment thereof can be prepared and isolated using any technique that provides for the production of antibody molecules by continuous cell lines in culture.
  • Techniques for production and isolation include but are not limited to the hybridoma technique originally described by Kohler and Milstein (1975); the human B-cell hybridoma technique (Cote et al., 1983); and the EBV-hybridoma technique (Cole et al. 1985).
  • Antibodies useful in practicing the present invention also include anti-NGAL or anti SERPINA3 fragments including but not limited to F(ab′)2 fragments, which can be generated by pepsin digestion of an intact antibody molecule, and Fab fragments, which can be generated by reducing the disulfide bridges of the F(ab′)2 fragments.
  • Fab and/or scFv expression libraries can be constructed to allow rapid identification of fragments having the desired specificity to NGAL or to SERPINA3.
  • phage display of antibodies may be used.
  • single-chain Fv (scFv) or Fab fragments are expressed on the surface of a suitable bacteriophage, e.g., M13.
  • a suitable host e.g., mouse
  • the coding regions of the VL and VH chains are obtained from those cells that are producing the desired antibody against the protein. These coding regions are then fused to a terminus of a phage sequence.
  • a suitable carrier e.g., bacteria
  • the phage displays the antibody fragment.
  • Phage display of antibodies may also be provided by combinatorial methods known to those skilled in the art. Antibody fragments displayed by a phage may then be used as part of an immunoassay.
  • Monoclonal antibodies for NGAL are described, for example, in Kjeldsen et al., (1996).
  • Examples of commercially available monoclonal antibodies for NGAL include those obtained from the Antibody Shop, Copenhagen, Denmark, as HYB-211-01, HYB-211-02, and NYB-211-05.
  • HYB-211-01 and HYB-211-02 can be used with NGAL in both its reduced and unreduced forms.
  • NGAL antibodies can also be purchased from R&D Systems under reference AF1857.
  • Examples of commercially available monoclonal antibodies for SERPINA3 include those obtained from Abgent, Inc. San Diego and from Sigma-Aldrich Co.
  • the binding partner may be an aptamer.
  • Aptamers are a class of molecule that represents an alternative to antibodies in term of molecular recognition. Aptamers are oligonucleotide or oligopeptide sequences with the capacity to recognize virtually any class of target molecules with high affinity and specificity.
  • ligands may be isolated through Systematic Evolution of Ligands by EXponential enrichment (SELEX) of a random sequence library, as described in Tuerk C. 1997.
  • the random sequence library is obtainable by combinatorial chemical synthesis of DNA. In this library, each member is a linear oligomer, eventually chemically modified, of a unique sequence. Possible modifications, uses and advantages of this class of molecules have been reviewed in Jayasena S.
  • Peptide aptamers consist of conformationally constrained antibody variable regions displayed by a platform protein, such as E. coli Thioredoxin A, that are selected from combinatorial libraries by two hybrid methods (Colas et al., 1996).
  • binding partners of the invention such as antibodies or aptamers, may be labelled with a detectable molecule or substance, such as a fluorescent molecule, a radioactive molecule or any others labels known in the art.
  • a detectable molecule or substance such as a fluorescent molecule, a radioactive molecule or any others labels known in the art.
  • Labels are known in the art that generally provide (either directly or indirectly) a signal.
  • the term “labelled”, with regard to the antibody is intended to encompass direct labelling of the antibody or aptamer by coupling (i.e., physically linking) a detectable substance, such as a radioactive agent or a fluorophore (e.g. fluorescein isothiocyanate (FITC) or phycoerythrin (PE) or Indocyanine (Cy5)) to the antibody or aptamer, as well as indirect labelling of the probe or antibody by reactivity with a detectable substance.
  • a detectable substance such as a radioactive agent or a fluorophore (e.g. fluorescein isothiocyanate (FITC) or phycoerythrin (PE) or Indocyanine (Cy5)
  • FITC fluorescein isothiocyanate
  • PE phycoerythrin
  • Indocyanine Indocyanine
  • An antibody or aptamer of the invention may be labelled with a radioactive molecule by any method known in the art.
  • the aforementioned assays generally involve the binding of the binding partner (ie. Antibody or aptamer) to a solid support.
  • Solid supports which can be used in the practice of the invention include substrates such as nitrocellulose (e.g., in membrane or microtiter well form); polyvinylchloride (e.g., sheets or microtiter wells); polystyrene latex (e.g., beads or microtiter plates); polyvinylidine fluoride; diazotized paper; nylon membranes; activated beads, magnetically responsive beads, and the like.
  • the concentration of one or two biomarkers proteins may be measured by using standard immunodiagnostic techniques, including immunoassays such as competition, direct reaction, or sandwich type assays.
  • immunoassays such as competition, direct reaction, or sandwich type assays.
  • assays include, but are not limited to, agglutination tests; enzyme-labelled and mediated immunoassays, such as ELISAs; biotin/avidin type assays; radioimmunoassays; immunoelectrophoresis; immunoprecipitation.
  • an ELISA method can be used, wherein the wells of a microtiter plate are coated with a set of antibodies which recognize said one or two biomarkers proteins. A biological sample containing or suspected of containing said one or two biomarkers proteins is then added to the coated wells. After a period of incubation sufficient to allow the formation of antibody-antigen complexes, the plate(s) can be washed to remove unbound moieties and a detectably labelled secondary binding molecule added. The secondary binding molecule is allowed to react with any captured sample marker protein, the plate washed and the presence of the secondary binding molecule detected using methods well known in the art.
  • Suitable ELISA methods for the detection of NGAL were described in Kjeldsen et al. (1996), Mishra J. et al. (2005) and Wang et al. (2007).
  • a sandwich enzyme immunoassay for the detection of NGAL was described by Blaser J. et al. (1995).
  • a radioimmunoassay for the detection of NGAL was described by Xu S Y. et al. (1994).
  • ELISA kits for detecting NGAL are commercially available from AntibodyShop (Grusbakken 8 DK-2820 Gentofte—Denmark) under the reference KIT 036 or KIT 037, from R&D Systems Europe (Lille—France) under the reference DLCN20 and from MBL International, Woburn, Mass. 01801, USA) under reference CY-8070.
  • An immunoassay for quantifying NGAL/MMP9 complex concentrations is commercially available from R&D Systems Europe (Lille—France) under the reference DM9L20.
  • Measuring the concentration of the one or two biomarkers proteins may also include separation of the compounds: centrifugation based on the compound's molecular weight; electrophoresis based on mass and charge; HPLC based on hydrophobicity; size exclusion chromatography based on size; and solid-phase affinity based on the compound's affinity for the particular solid-phase that is used.
  • said one or two biomarkers proteins may be identified based on the known “separation profile” e.g., retention time, for that compound and measured using standard techniques.
  • the separated compounds may be detected and measured by, for example, a mass spectrometer.
  • the method of the invention further may comprise a step of comparing the concentration of said one or two biomarkers proteins with a predetermined threshold value. Said comparison is indicative of the MR activation in the patient or the responsiveness of the patient to the treatment with a MR antagonist.
  • a human patient can be deemed to be a responder to treatment if the concentration of the blood NGAL protein prior to treatment is higher than 70 ⁇ g/l, preferably higher than 80 ⁇ g/l, even more preferably higher than 85 ⁇ g/l 90 ⁇ g/l, 95 ⁇ g/l, 100 ⁇ g/l, 125 ⁇ g/l, 150 ⁇ g/l or 200 ⁇ g/l.
  • kits comprising materials useful for carrying out the method for assessing the MR activation in a patient and the method for predicting the responsiveness of a patient to a treatment with a MR antagonist or an aldosterone synthase inhibitor. These methods may be performed by diagnostics laboratories, experimental laboratories or practitioners. The invention provides kits that can be used in these different settings.
  • Material and reagents for detecting NGAL and/or SERPINA3 in a biological sample may be assembled together in a kit.
  • kit comprises:
  • binding partner is an antibody
  • the binding partner can be tagged for an easier detection. It may or may not be immobilized on a substrate surface (e.g., beads, array, and the like). Typically, a substrate surface (e.g. membrane) may be included in the kit for immobilization of the binding partner (e.g., via gel electrophoresis and transfer to membrane).
  • a substrate surface e.g. membrane
  • the kit for immobilization of the binding partner (e.g., via gel electrophoresis and transfer to membrane).
  • kits of the invention generally also comprises at least one reagent for the detection of a complex between binding partner included in the kit and biomarker of the invention.
  • the kit may further comprise one or more of: extraction buffer and/or reagents, western blotting buffer and/or reagents, and detection means. Protocols for using these buffers and reagents for performing different steps of the procedure may be included in the kit.
  • kits of the present invention may optionally comprise different containers (e.g., vial, ampoule, test tube, flask or bottle) for each individual buffer and/or reagent.
  • Each component will generally be suitable as aliquoted in its respective container or provided in a concentrated form.
  • Other containers suitable for conducting certain steps of the disclosed methods may also be provided.
  • the individual containers of the kit are preferably maintained in close confinement for commercial sale.
  • a kit comprises instructions for using its components for the prediction of a heart failure risk in a subject according to a method of the invention.
  • Instructions for using the kit according to methods of the invention may comprise instructions for processing the biological sample obtained from the subject and/or for performing the test, or instructions for interpreting the results.
  • a kit may also contain a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products.
  • the method of the invention may be useful for classifying patients affected by cardiovascular disease and then may be used to choose the accurate treatment for said patient. For example, patients classified as responder or non responder may thus receive an appropriate amount of the MR antagonist or aldosterone synthase inhibitor. Such a method may thus help the physician to make a choice on a therapeutic treatment. Costs of the treatments may therefore be adapted to risk of the patients.
  • Another aspect of the invention relates to a method for treating a patient affected with and/or preventing in a patient at risk of a disease comprising the steps consisting in:
  • said disease is a cardiovascular disease.
  • said disease is metabolic syndrome, obesity or diabetes.
  • the MR antagonist or aldosterone synthase inhibitor may be administered in the form of a pharmaceutical composition.
  • said antagonist or inhibitor is administered in a therapeutically effective amount.
  • a “therapeutically effective amount” is meant a sufficient amount of the MR antagonist or inhibitor to treat and/or to prevent cardiovascular disease at a reasonable benefit/risk ratio applicable to any medical treatment.
  • the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment.
  • the specific therapeutically effective dose level for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder; activity of the specific compound employed; the specific composition employed, the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific polypeptide employed; and like factors well known in the medical arts.
  • the daily dosage of the products may be varied over a wide range from 0.01 to 1,000 mg per adult per day.
  • the compositions contain 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100, 250 and 500 mg of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated.
  • a medicament typically contains from about 0.01 mg to about 500 mg of the active ingredient, preferably from 1 mg to about 100 mg of the active ingredient.
  • An effective amount of the drug is ordinarily supplied at a dosage level from 0.0002 mg/kg to about 20 mg/kg of body weight per day, especially from about 0.001 mg/kg to 7 mg/kg of body weight per day.
  • a further object of the invention is the use of a MR antagonist or an aldosterone synthase inhibitor, for the preparation of a medicament for treating a patient affected with a cardiovascular disease, diabetes, obesity or metabolic syndrome, said patient being classified as responder by the method as above described.
  • a further object of the invention relates to a MR antagonist or an aldosterone synthase inhibitor for treating a patient affected with a cardiovascular disease, diabetes, obesity or metabolic syndrome, said patient being classified as responder by the method of the invention.
  • a further object of the invention thus relates to a MR antagonist or an aldosterone synthase inhibitor for treating a patient affected with a cardiovascular disease, diabetes, obesity or metabolic syndrome, wherein said patient has an expression level of said one or two biomarkers higher than a predetermined value obtained from the general population or from healthy subjects.
  • said patient is affected with a cardiovascular disease.
  • said patient is affected with obesity.
  • said patient is affected with diabetes.
  • said patient is affected with metabolic syndrome.
  • Another object of the invention is the use of one or two biomarkers selected from the group consisting of the Neutrophil Gelatinase-Associated Lipocalin (NGAL) gene and the SERPINA3 gene, as biomarker(s) of MR activation in a patient.
  • NGAL Neutrophil Gelatinase-Associated Lipocalin
  • Another object of the invention is a method for monitoring a treatment of a patient with a MR antagonist or an aldosterone synthase inhibitor comprising assessing the MR activation by the method according to the invention, and optionally, comparing the expression level of said one or two biomarkers with a predetermined value representing a predetermined stage of the MR activation, the expression level of said one or two biomarkers with respect to the predetermined value indicating the evolution of the MR activation, and therefore the degree of efficacy of the treatment.
  • FIG. 1A Time course of NGAL expression in models with conditional MR cardiac overexpression.
  • Lcn2 stands for lipocalin2 (NGAL).
  • HPRT stands for housekeeping control gene.
  • Cnt stands for control littermate mice.
  • DT stands for double-transgenic mice with conditional hMR overexpression.
  • FIG. 1B NGAL protein expression in the heart of MR.
  • Lcn2 stands for lipocalin2 (NGAL).
  • GAPDH stands for housekeeping control protein.
  • Cnt stands for control littermate mice.
  • DT stands for double-transgenic mice with conditional hMR overexpression.
  • FIG. 2 NGAL expression in the heart of MR versus GR overexpressing mice.
  • Lcn2 stands for lipocalin2 (NGAL).
  • HPRT stands for housekeeping control gene.
  • Cnt stands for control littermate mice.
  • DT stands for double-transgenic mice with conditional hMR or hGR overexpression.
  • FIG. 3 NGAL expression in various models.
  • a and B quantitative PCR
  • C and D ELISA.
  • Cnt stands for control littermate mice.
  • DT stands for double-transgenic mice with conditional hMR overexpression.
  • Aldo-salt means uninephrectomized mice treated with aldosterone infusion and drinking 1% NaCl.
  • Endothelial-specific MR expression is obtained by conditional MR expression targeted to the endothelium only.
  • FIG. 4 Expression of NGAL in a cellular model of rat cardiomyocyte (H9C2 cells) stably expressing rat MR.
  • Cnt stands for control (diluent).
  • Aldo and cortico stand for aldosterone and corticosterone, respectively.
  • RU28318 is an MR antagonist,
  • RU 486 is a GR antagonist.
  • ⁇ actin is a housekeeping gene used for normalization.
  • FIG. 5A Expression of NGAL in a mouse model of type II diabetes.
  • Lcn2 stands for lipocalin2 (NGAL).
  • Cnt stands for control littermate mice.
  • Db/db stands for diabetic mice.
  • FIG. 5B Evolution of the lipocalin2/NGAL plasma levels. Plasma Icn2 in control and db/db mice, with or without treatment with canrenoate for 17 weeks.
  • FIG. 6 MR-dependent induction of lipocalin2/NGAL in the heart and plasma of rats with cardiac failure.
  • A. The expression of lipocalin2/NGAL is increased 2-fold in the cardiac left ventricle of rats with cachexia-induced heart failure. Induction is fully prevented by effective dose of spironolactone (50 mg/Kg/day, able to prevent heart failure symptoms).
  • B. Plasma levels of lipocalin2/NGAL are also increased in the plasma of the rat with heart failure ( FIG. 6B ). The increase is prevented when animals are treated with spiro 50 mg/Kg/j (HF+spiro 50 mg/Kg/j versus HF).
  • FIG. 7 Validation of differential genes identified in microarray analysis on the mouse model of cardiac overexpression of MR.
  • the expression of Serpina3 is significantly increased in the heart of mice overexpressing the MR (DT-MR), but not modified in the heart of mice overexpressing the GR(DT-GR).
  • Values of mRNA levels were normalized for ubc mRNA levels in each sample. These values in control were set as 1 for each gene, and fold changes are shown on the figure.
  • FIG. 8 MR specificity of the Expression of serpina3 in H9C2/MR cells.
  • the expression of serpina3 is increased by 1 nM aldosterone (aldo) and 10 nM corticosterone (cortico) for 24 h, via a MR-dependant mechanism as shown using the RU28318, a specific MR antagonist.
  • Values of mRNA levels were normalized for ⁇ -actin mRNA levels in each sample. These values in control (nontreated cells) were set as 1 for each gene, and fold changes are shown on the figure. **, p ⁇ 0.01 vs. control (no steroid), using ANOVA analysis.
  • FIG. 9A time-course of Serpina3 induction in H9C2/MR cells treated with 10 nM aldosterone.
  • Serpina3 expression is highly induced after 24 h exposure to aldosterone. Values of mRNA levels were normalized for ⁇ -actin mRNA levels in each sample. These values in control (nontreated cells) were set as 1 for each gene, and fold changes are shown on the figure. *, p ⁇ 0.05, **, p ⁇ 0.01 vs. control (no steroid), using ANOVA analysis.
  • FIG. 9B Dose-response of Serpina3 induction with aldosterone.
  • FIG. 10 MR-dependent induction of Serpina3 in the heart of rats with cardiac failure.
  • Serpina3 is highly increased in the cardiac left ventricle of rats with cachexia-induced heart failure. Induction is prevented by effective dose of spironolactone (50 mg/Kg/day, able to prevent heart failure symptoms). **, p ⁇ 0.01 vs. sham #, p ⁇ 0.05, vs. Placebo (heart failure, placebo administration) using ANOVA analysis.
  • MR and GR transgenic mice Mineralocorticoid receptor (MR) and glucocorticoid receptor (GR) transgenic mice allowed conditional expression of the human MR or GR, respectively.
  • MR and GR transgenic mice were obtained by breeding the in-house generated acceptor mice that allowed conditional, inducible expression of hMR or hGR when crossed with appropriate transactivator mice. These conditional transgenic models have been described in Ouvrard-Pascaud et al. (2005) and Sainte-Marie et al. (2007). To identify genes selectively modulated by MR in the heart, the MR and GR acceptor mice were crossed with the MHC-tTA transactivator mice provided by G.
  • mRNA from MR transgenic mice was pooled and labelled with Cy5 in three separate reactions.
  • mRNA from the reference for MR transgenic mice was pooled and labeled with Cy3 in three separate reactions.
  • mRNA from GR transgenic mice was combined into three pools that were each labeled with Cy5 in two separate reactions.
  • mRNA from the reference for GR transgenic mice was pooled and labeled with Cy3 in six separate reactions.
  • Cy3- and Cy5-labeled cDNA was prepared using the CyScribe cDNA Post Labeling Kit (Amersham Pharmacia Biotech). Labeling reactions were performed separately for each microarray. Three microarray hybridizations were performed for the MR transgenic mice and six for the GR transgenic mice. The hybridization mixture was pre-incubated with human Cot-I DNA (Gibco-BRL), yeast tRNA and polyA RNA and hybridized to a microarray.
  • Microarrays were prepared in-house using 50-mer oligonucleotide probes (MWG Biotech®). The probes were spotted onto epoxy-silane coated glass slides using the Lucidea Array Spotter from Amersham. The 5419 genes that were represented on the microarray had been selected for involvement in cardiovascular and/or skeletal muscle normal and pathological functioning. Selection was based on 1) subtractive hybridization experiments (Steenman et al. 2005), 2) genome-wide microarray hybridizations (Steenman et al. 2003) and 3) literature data. The microarray contained both mouse-specific oligonucleotides and human oligonucleotides with at least 80% homology with the corresponding mouse sequence. Each gene probe was spotted in triplicate.
  • Hybridized arrays were scanned by fluorescence confocal microscopy (Scanarray 4000XL, GSI-Lumonics). Fluorescence signal measurements were obtained separately for each fluorochrome at a 10 ⁇ m/pixel resolution. Hybridization and background signal intensities, and quality control parameters were measured using GenePix Pro 5.0 (Axon®). A Lowess normalization procedure (Yang et al. 2002) was performed to correct for technical biases. The procedure was applied channel-by-channel as described previously (Workman et al. 2002). For each microarray, Cy3- and Cy5-signal intensities were individually normalized to a prototype defined as the median profile of all Cy3- or Cy5-signal intensities.
  • Quantitative NGAL mRNA expression was analyzed by quantitative PCR (Q-PCR, Light Cycler, Biorad) using forward 5′-GGACCAGGGCTGTCGCTACT-3′ (SEQ ID NO:1) and Reverse 5′-GGTGGCCACTTGCACATTGT-3′ (SEQ ID NO:2) primers on 25 ⁇ l of RT-PCR (using the qPCR Core kit for Sybr Green I from Eurogentec) prepared using 2 ⁇ g DNA-free total RNA extracted from the heart of one, two and three mo-old MR transgenic mice and compared to matched littermates, as well as two mo-old GR transgenic mice (and respective control littermates).
  • NGAL protein expression of NGAL was analyzed in cardiac protein extracts from two mo-old MR mice using a specific NGAL antibody (AF1857, R&D Systems). Plasma concentration of NGAL was estimated using a murine NGAL-specific ELISA assay (provided by A. Xu, Hong-Kong) (Wang et al., 2007)
  • Quantitative NGAL mRNA expression was also analyzed by Q-PCR in the heart of mice with uninephrectomy and treated with aldosterone infusion (60 ⁇ g/kg/j, 0.25 ⁇ l/h ALZET minipumps) and 1% salt in the drinking water for 3 weeks (as compared to uninephrectomized-only control mice), and in thoracic aorta from 9 months-old mice with conditional overexpression of the human MR in the endothelium only obtained after appropriate breeding of the MR transgenic mice described above with an endothelial-specific transactivator mice (provided by L. E. Benjamine, Harvard, USA) (Sun et al., 2005) that allowed conditional expression of hMR in the endothelium only.
  • Plasma concentration of NGAL was also estimated in the plasma of 3 mo mice with uninephrectomy and treated with aldosterone infusion (60 ⁇ g/kg/j, 0.25 ⁇ l/h ALZET minipumps) and 1% salt in the drinking water for 3 weeks (as compared to uninephrectomized-only control mice) as well as in 9-mo old mice with endothelial-specific MR overexpression, as compared to control littermates.
  • Quantitative NGAL mRNA expression was analyzed by quantitative PCR (Q-PCR, Light Cycler, Biorad) using forward 5′-TCACCCTGTACGGAAGAACC-3′ (SEQ ID NO:3) and reverse 5′-GGTGGGAACAGAGAAAACGA-3′ (SEQ ID NO:4) primers on 25 ⁇ l of RT-PCR (using the qPCR Core kit for Sybr Green I from Eurogentec) prepared using 2 ⁇ g DNA-free total RNA extracted from rat H9-C2/MR cells treated with various concentrations of aldosterone or 10 ⁇ 8 M corticosterone or 10 ⁇ 8 M MR antagonist RU 28318 or GR antagonist RU 486, alone or in combination.
  • Plasma concentration of NGAL was estimated using a murine NGAL-specific ELISA assay (provided by A. Xu, Hong-Kong) (Wang et al., 2007) in db/db mice before and after treatment with the pharmacological MR antagonist canrenoate (Canrenoate, Sigma-Alderich, 100 mg/Kg/day in the drinking water, 45 days).
  • Lipocalin2/NGAL mRNA is strongly expressed ( ⁇ 60-200) in the heart of mice with conditional human MR overexpression (DT) as compared to control littermates (Cnt) at 1, 1.5 or 3 mo of age ( FIG. 1A ). Lipocalin2/NGAL protein was also strongly induced in the heart of 1.5 mo-old mice with conditional human MR overexpression (DT) as compared to control littermates (Cnt) ( FIG. 1B ). This is highly sensitive since induction of lipocalin2/NGAL expression in control littermates never exceeded ⁇ 1.3. Specificity over the closely related GR was assessed by analyzing lipocalin/NGAL expression in the heart of 2 mo-old GR overexpressing mice ( FIG. 2 ). NGAL expression was 75 fold more induced in the heart of MR-overexpressing mice than in GR-overexpressing mice.
  • Lipocalin2/NGAL expression is increased in the heart of mice with 3 weeks pharmacological MR stimulation (aldo/salt model) as well as in the aorta of 9 months-old mice with conditional MR overexpression targeted to the endothelium (DT, as compared to littermates, Cnt) ( FIG. 3 A-C).
  • DT endothelium
  • Cnt littermates
  • Lipocalin2/NGAL expression is increased in H9C2/MR cells treated with 10 ⁇ 8 M aldosterone for 24 h ( FIG. 4A ). This increase of Lipocalin2/NGAL expression is prevented by the addition to 10 ⁇ 8 M aldosterone of the MR antagonist RU 28318 but not of the GR antagonist RU 486 ( FIG. 4A ). 10 ⁇ 8 M Corticosterone (a glucocorticoid hormone) also stimulated Lipocalin2/NGAL expression in H9C2/MR cells ( FIG. 4B ). This increase is also prevented by the MR antagonist RU 28318 but not by the GR antagonist RU 486 ( FIG.
  • FIG. 5B represents the lipocalin2/NGAL plasma levels in control and db/db mice mice, with or without treatment with canrenoate.
  • the increase in plasma levels of lipocalin2/NGAL in db/db mice is prevented by 17 weeks in vivo treatment of the db/db mice with the MR antagonist canrenoate ( FIG. 5B , db/db+canrenoate).
  • Canrenoate has no effect on the plasma levels of lipocalin2/NGAL in control mice (control+canrenoate). This demonstrates that plasma level lipocalin2/NGAL can be used to follow efficacy of MR antagonists in type II diabetes.
  • FIG. 6A In a rat model of heart failure (HF) associated to cachexia, cardiac lipocalin2/NGAL mRNA expression, as estimated by real time PCR, is induced up to 2 fold (sham versus MI) ( FIG. 6A ).
  • spironolactone is administered to an efficient concentration to prevent the development of heart failure symptom (HF+spiro 50 mg/Kg/j versus HF)
  • induction of lipocalin2/NGAL mRNA is fully prevented ( FIG. 6A ).
  • Plasma levels of lipocalin2/NGAL are also increased in the plasma of the rat with heart failure ( FIG. 6B ). The increase is prevented when animals are treated with spiro 50 mg/Kg/j (HF+spiro 50 mg/Kg/j versus HF).
  • MR activation can be specifically and efficiently assessed by determining the expression level of the NGAL gene.
  • the responsiveness of a patient to a treatment with a MR antagonist or an aldosterone synthase inhibitor can be predicted by determining the expression level of the NGAL gene in a biological sample obtained from said patient.
  • the plasma level of Lcn2/NGAL has been measured in a population of healthy subjects.
  • known high blood pressure greater than 140/90 mmHg or greater than 160 mm Hg if older than 65
  • known renal failure known diabetes, pregnancy, cancer diagnosed within the past 5 years or evolutive neoplasia, chronic liver pathology, connectivitis, Crohn's disease, evolutive tuberculosis, exertional angina, acute
  • the plasma level of Lcn2/NGAL of the healthy subjects was generally comprised between 40 and 80 ⁇ g/ml.
  • the plasma level of Lcn2/NGAL of patients affected with a cardiovascular disease, diabetes, obesity or metabolic syndrome is also measured. It is higher than that of the healthy subjects.
  • Cardiomyocyte MR overexpression for 6 weeks resulted in about 24 up-regulated and 23 down-regulated genes.
  • most of them differed from GR-regulated genes that were determined in parallel in GR-cardiac mice (about 74 GR up-regulated genes and 70 GR down-regulated genes).
  • most of the MR-regulated genes did not change in the GR-cardiac mouse model, indicating that each steroid receptor controls a distinct pattern of gene expression in cardiomyocytes.
  • MR and GR transgenic mice Mineralocorticoid receptor (MR) and glucocorticoid receptor (GR) transgenic mice allowed conditional expression of the human MR or GR, respectively.
  • MR and GR transgenic mice were obtained by breeding the in-house generated acceptor mice that allowed conditional, inducible expression of hMR or hGR when crossed with appropriate transactivator mice. These conditional transgenic models have been described in Ouvrard-Pascaud et al. (2005) and Sainte-Marie et al. (2007). To identify genes selectively modulated by MR in the heart, the MR and GR acceptor mice were crossed with the MHC-tTA transactivator mice provided by G.
  • mRNA from MR transgenic mice was pooled and labelled with Cy5 in three separate reactions.
  • mRNA from the reference for MR transgenic mice was pooled and labeled with Cy3 in three separate reactions.
  • mRNA from GR transgenic mice was combined into three pools that were each labeled with Cy5 in two separate reactions.
  • mRNA from the reference for GR transgenic mice was pooled and labeled with Cy3 in six separate reactions.
  • Cy3- and Cy5-labeled cDNA was prepared using the CyScribe cDNA Post Labeling Kit (Amersham Pharmacia Biotech). Labeling reactions were performed separately for each microarray. Three microarray hybridizations were performed for the MR transgenic mice and six for the GR transgenic mice. The hybridization mixture was pre-incubated with human Cot-I DNA (Gibco-BRL), yeast tRNA and polyA RNA and hybridized to a microarray.
  • Microarrays were prepared in-house using 50-mer oligonucleotide probes (MWG Biotech®). The probes were spotted onto epoxy-silane coated glass slides using the Lucidea Array Spotter from Amersham. The 5419 genes that were represented on the microarray had been selected for involvement in cardiovascular and/or skeletal muscle normal and pathological functioning. Selection was based on 1) subtractive hybridization experiments (Steenman et al. 2005), 2) genome-wide microarray hybridizations (Steenman et al. 2003) and 3) literature data. The microarray contained both mouse-specific oligonucleotides and human oligonucleotides with at least 80% homology with the corresponding mouse sequence. Each gene probe was spotted in triplicate.
  • Hybridized arrays were scanned by fluorescence confocal microscopy (Scanarray 4000XL, GSI-Lumonics). Fluorescence signal measurements were obtained separately for each fluorochrome at a 10 ⁇ m/pixel resolution. Hybridization and background signal intensities, and quality control parameters were measured using GenePix Pro 5.0 (Axon®). A Lowess normalization procedure (Yang et al. 2002) was performed to correct for technical biases. The procedure was applied channel-by-channel as described previously (Workman et al. 2002). For each microarray, Cy3- and Cy5-signal intensities were individually normalized to a prototype defined as the median profile of all Cy3- or Cy5-signal intensities.
  • Quantitative Serpina3 mRNA expression was analyzed by quantitative PCR (Q-PCR, Light Cycler, Biorad) using forward 5′-CATCCCTGTGGGAAGTCAGT-3′ (SEQ ID NO:5) and Reverse 5′-CTTTTGGGTGGAGGCAGATA-3′ (SEQ ID NO:6) primers on 25 ⁇ l of RT-PCR (using the qPCR Core kit for Sybr Green I from Eurogentec) prepared using 2 ⁇ g DNA-free total RNA extracted from the heart of one, two and three mo-old MR transgenic mice and compared to matched littermates, as well as two mo-old GR transgenic mice (and respective control littermates)
  • Quantitative Serpina3 mRNA expression was analyzed by quantitative PCR (Q-PCR, Light Cycler, Biorad) using forward 5′-AGACAAGGGGACACAACTGG-3′ (SEQ ID NO:7) and reverse 5′-TGAGATGCTAAGTGGGGAGAA-3′ (SEQ ID NO:8) primers on 25 ⁇ l of RT-PCR (using the qPCR Core kit for Sybr Green I from Eurogentec) prepared using 2 ⁇ g DNA-free total RNA extracted from rat H9-C2/MR cells treated with various concentrations of aldosterone or 10 ⁇ 8 M corticosterone or 10 ⁇ 6 M MR antagonist RU 28318, alone or in combination.
  • Quantitative Serpina3 mRNA expression was analyzed by quantitative PCR (Q-PCR, Light Cycler, Biorad) using forward 5′-AGACAAGGGGACACAACTGG-3′ (SEQ ID NO:7) and reverse 5′-TGAGATGCTAAGTGGGGAGAA-3′ (SEQ ID NO:8) primers on 25 ⁇ l of RT-PCR (using the qPCR Core kit for Sybr Green I from Eurogentec) prepared using 2 ⁇ g DNA-free total RNA extracted from the left ventricles
  • SERPINA3 are involved in the early response to aldosterone in cardiomyocytes, as well as in the chronic adaptation to enhanced MR signaling, as seen in mice overexpressing the MR. Because serpina3 is a secreted enzymes, it can be used as markers of cardiac damage linked to MR activation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
US13/124,575 2008-10-24 2009-10-21 Biomarkers of Mineralocorticoid Receptor Activation Abandoned US20110257140A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/124,575 US20110257140A1 (en) 2008-10-24 2009-10-21 Biomarkers of Mineralocorticoid Receptor Activation

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP08305728 2008-10-24
EP08305728.1 2008-10-24
US18182109P 2009-05-28 2009-05-28
US13/124,575 US20110257140A1 (en) 2008-10-24 2009-10-21 Biomarkers of Mineralocorticoid Receptor Activation
PCT/EP2009/063832 WO2010046411A1 (en) 2008-10-24 2009-10-21 Biomarkers of mineralocorticoid receptor activation

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/063832 A-371-Of-International WO2010046411A1 (en) 2008-10-24 2009-10-21 Biomarkers of mineralocorticoid receptor activation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/188,198 Continuation US10041122B2 (en) 2008-10-24 2016-06-21 Biomarkers of mineralocorticoid receptor activation

Publications (1)

Publication Number Publication Date
US20110257140A1 true US20110257140A1 (en) 2011-10-20

Family

ID=40379567

Family Applications (2)

Application Number Title Priority Date Filing Date
US13/124,575 Abandoned US20110257140A1 (en) 2008-10-24 2009-10-21 Biomarkers of Mineralocorticoid Receptor Activation
US15/188,198 Active US10041122B2 (en) 2008-10-24 2016-06-21 Biomarkers of mineralocorticoid receptor activation

Family Applications After (1)

Application Number Title Priority Date Filing Date
US15/188,198 Active US10041122B2 (en) 2008-10-24 2016-06-21 Biomarkers of mineralocorticoid receptor activation

Country Status (10)

Country Link
US (2) US20110257140A1 (zh)
EP (1) EP2344671B1 (zh)
JP (1) JP2012506245A (zh)
KR (1) KR20110081846A (zh)
CN (1) CN102197146B (zh)
AU (1) AU2009306404B2 (zh)
CA (1) CA2738944A1 (zh)
ES (1) ES2579210T3 (zh)
IL (2) IL212231A (zh)
WO (1) WO2010046411A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110143381A1 (en) * 2005-10-13 2011-06-16 Barasch Jonathan Matthew Diagnosis and monitoring of chronic renal disease using ngal
US10670611B2 (en) 2014-09-26 2020-06-02 Somalogic, Inc. Cardiovascular risk event prediction and uses thereof

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011156715A2 (en) * 2010-06-10 2011-12-15 The Regents Of The University Of Michigan Methods of treating metabolic disorders and cardiovascular diseases
WO2012059594A1 (en) * 2010-11-04 2012-05-10 Bayer Pharma Aktiengesellschaft Mineralcorticoid receptor antagonists for the treatment of corticoid-induced obesity
WO2012072820A1 (en) * 2010-12-03 2012-06-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of heart failure
WO2013156867A2 (en) * 2012-04-19 2013-10-24 Inserm Methods and pharmaceutical compositions for the treatment of hypertension
WO2014049152A1 (en) * 2012-09-28 2014-04-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cardiovascular fibrosis
WO2016005424A1 (en) * 2014-07-09 2016-01-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for assessing mineralocorticoid receptor activation in adipose tissue of a subject and treating metabolic syndrome
EP3651807B1 (en) * 2017-07-13 2023-11-01 City of Hope Phosphorothioate-conjugated peptides and methods of using the same
CN109880916B (zh) * 2019-04-10 2022-03-18 山东省农业科学院家禽研究所 一种与鸡繁殖性状相关的nr3c2基因的分子标记及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002009683A2 (en) * 2000-07-27 2002-02-07 Pharmacia Corporation Aldosterone blocker therapy to prevent or treat inflammation-related disorders
EP2003196A3 (en) * 2003-06-09 2009-01-07 The Regents of the University of Michigan Compositions and methods for treating and diagnosing cancer
EP2062054A1 (en) * 2006-09-05 2009-05-27 Beth Israel Deaconess Medical Center, Inc. Use of lipocalin 2 in the regulation of insulin sensitivity
WO2008060607A2 (en) * 2006-11-14 2008-05-22 Biosite Incorporated Methods and compositions for monitoring and risk prediction in cardiorenal syndrome
WO2012072820A1 (en) * 2010-12-03 2012-06-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of heart failure
WO2013156867A2 (en) * 2012-04-19 2013-10-24 Inserm Methods and pharmaceutical compositions for the treatment of hypertension
WO2014049152A1 (en) * 2012-09-28 2014-04-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cardiovascular fibrosis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Yan et al. (Diabetes 56: 2533-2540, 2007). *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110143381A1 (en) * 2005-10-13 2011-06-16 Barasch Jonathan Matthew Diagnosis and monitoring of chronic renal disease using ngal
US10670611B2 (en) 2014-09-26 2020-06-02 Somalogic, Inc. Cardiovascular risk event prediction and uses thereof

Also Published As

Publication number Publication date
US10041122B2 (en) 2018-08-07
WO2010046411A1 (en) 2010-04-29
EP2344671B1 (en) 2016-04-13
EP2344671A1 (en) 2011-07-20
ES2579210T3 (es) 2016-08-08
US20160362744A1 (en) 2016-12-15
IL212231A (en) 2014-09-30
AU2009306404A1 (en) 2010-04-29
AU2009306404B2 (en) 2015-01-15
IL227751A0 (en) 2013-09-30
JP2012506245A (ja) 2012-03-15
IL227751A (en) 2014-09-30
CN102197146B (zh) 2014-06-04
CA2738944A1 (en) 2010-04-29
KR20110081846A (ko) 2011-07-14
CN102197146A (zh) 2011-09-21
IL212231A0 (en) 2011-06-30

Similar Documents

Publication Publication Date Title
US10041122B2 (en) Biomarkers of mineralocorticoid receptor activation
US7666608B2 (en) Methods for determining drug responsiveness
JP2008515394A (ja) 心臓の圧負荷関連遺伝子
EP2710143B1 (en) Method for determining whether a subject is at risk of having or developing a chronic kidney disease
JP2010185878A (ja) 栄養膜細胞の細胞死、分化、浸潤、および／または細胞融合および代謝回転に関連する状態の診断用組成物および治療方法
JP2009529659A5 (zh)
US20040203031A1 (en) Methods for determining drug responsiveness
AU2014250689A1 (en) Biomarkers of Mineralocorticoid Receptor activation
WO2010133655A1 (en) Post-translation modified cardiac troponin t as a biomarker of a risk for heart failure
US20160376657A1 (en) Method of diagnosing renal disorders
WO2008129265A1 (en) Diagnostics and therapeutics for diabetic nephropathy involving ccl18
CA2744508A1 (en) Use of alpha-2-macroglobulin for determining osteonecrosis disease status and for screening therapeutic agents for treating osteonecrosis
JP2023544387A (ja) 虚血後の心臓リモデリングにおけるバイオマーカー及びバイオターゲットとしてのｇｄｆ３
US20080313751A1 (en) Method by Using Human or Mice-Isg12 to Develop and Prepare Drugs and Single Nucleotide Polymorphism in the Isg12 Gene for Diagnostic Use
US20110268742A1 (en) Pctp modulators in the treatment of acne, of seborrhoeic dermatitis or of hyperseborrhoea
WO2011039171A1 (en) Vasoactive peptide and derivatives thereof
WO2009135913A1 (en) Modulators of carnitine octanoyltransferase in the treatment of acne, of seborrhoeic dermatitis or of hyperseborrhoea

Legal Events

Date Code Title Description
AS Assignment

Owner name: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA REC

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:JAISSER, FREDERIC;FARMAN, NICOLETTE;SAINTE-MARIE, YANNIS;AND OTHERS;SIGNING DATES FROM 20110418 TO 20110427;REEL/FRAME:026556/0338

AS Assignment

Owner name: UNIVERSITE PARIS DESCARTES, FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE;REEL/FRAME:033858/0145

Effective date: 20140922

Owner name: UNIVERSITE DE NANTES, FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE;REEL/FRAME:033858/0145

Effective date: 20140922

AS Assignment

Owner name: UNIVERSITE DE NANTES, FRANCE

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE OWNER OF THE PATENT RIGHTS. ASSIGNMENT IS NOT FOR ENTIRE INTEREST, BUT AN ASSIGNMENT IN PART. PREVIOUSLY RECORDED ON REEL 033858 FRAME 0145. ASSIGNOR(S) HEREBY CONFIRMS THE CONVEYING PARTY ASSIGNS ENTIRE INTEREST;ASSIGNOR:INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE;REEL/FRAME:035000/0312

Effective date: 20140922

Owner name: UNIVERSITE PARIS DESCARTES, FRANCE

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE OWNER OF THE PATENT RIGHTS. ASSIGNMENT IS NOT FOR ENTIRE INTEREST, BUT AN ASSIGNMENT IN PART. PREVIOUSLY RECORDED ON REEL 033858 FRAME 0145. ASSIGNOR(S) HEREBY CONFIRMS THE CONVEYING PARTY ASSIGNS ENTIRE INTEREST;ASSIGNOR:INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE;REEL/FRAME:035000/0312

Effective date: 20140922

Owner name: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE M

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE OWNER OF THE PATENT RIGHTS. ASSIGNMENT IS NOT FOR ENTIRE INTEREST, BUT AN ASSIGNMENT IN PART. PREVIOUSLY RECORDED ON REEL 033858 FRAME 0145. ASSIGNOR(S) HEREBY CONFIRMS THE CONVEYING PARTY ASSIGNS ENTIRE INTEREST;ASSIGNOR:INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE;REEL/FRAME:035000/0312

Effective date: 20140922

STCB Information on status: application discontinuation

Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION